SEC 13F Intelligence

Managers / Q1 2021 · view latest →

Consonance Capital Management LP

CIK 0001544773 · 1370 AVENUE OF THE AMERICAS, SUITE 3301, NEW YORK, NY, 10019 · 212.660-8062

Reported Value
$938M
Q1 2021
Positions
35
Filings on Record
15
2019–present window
Filed
May 17, 2021
original filing

Summary

Consonance Capital Management LP reported $938M in U.S.-listed holdings across 35 positions for Q1 2021.

Its largest position, UTHR, represents 10.0% of the portfolio.

Compared with Q4 2020, the fund opened 11 new positions and exited 14.

Portfolio Metrics

Turnover
+32.9%
vs prior filed quarter
Top-10 Concentration
+63.9%
share of reported value
Largest Position
+10.0%
United Therapeutics
New / Exited
11 / 14
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q1 ’19: $1.6BQ1 ’19Q2 ’19: $1.4BQ3 ’19: $1.0BQ3 ’19Q4 ’19: $1.6BQ1 ’20: $1.3BQ1 ’20Q2 ’20: $1.7BQ3 ’20: $821MQ3 ’20Q4 ’20: $1.1BQ1 ’21: $938MQ1 ’21Q2 ’21: $831MQ3 ’21: $183MQ3 ’21Q4 ’21: $153MQ1 ’22: $59MQ1 ’22Q2 ’22: $24MQ3 ’22: $7MQ3 ’22filingsflow.com

Portfolio Composition

By security type
Common Stock: 77.6%Other: 19.1%ADR: 3.3%
  • Common Stock · 77.6% · $728M
  • Other · 19.1% · $179M
  • ADR · 3.3% · $31M

Quarter-over-Quarter Changes full breakdown →

vs Q4 2020 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
AFFIMED N VNEW+6.01M6.01M+$48M$48M
TURNING POINT THERAPEUTICS INEW+450.4K450.4K+$43M$43M
LEGNLEGEND BIOTECH CORPNEW+896.6K896.6K+$26M$26M
INFIQINFINITY PHARMACEUTICALS INCNEW+6.58M6.58M+$21M$21M
NKTXNKARTA INCNEW+570.3K570.3K+$19M$19M
ADICET BIO INCNEW+1.22M1.22M+$16M$16M
CFMSCONFORMIS INCNEW+13.00M13.00M+$13M$13M
SLNSILENCE THERAPEUTICS PLCNEW+222.2K222.2K+$5M$5M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q1 2021

35 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1UTHRUNITED THERAPEUTICS CORP DELhistory →COM9.95%$93M558.2K
2SPRINGWORKS THERAPEUTICS INCCOM9.42%$88M1.20M
3MGNXMACROGENICS INChistory →COM8.39%$79M2.47M
4PTGXPROTAGONIST THERAPEUTICS INChistory →COM7.48%$70M2.71M
5KROSKEROS THERAPEUTICS INChistory →COM5.84%$55M890.2K
6AFFIMED N VCOM5.07%$48M6.01M
7DECIPHERA PHARMACEUTICALS INCOM4.75%$45M993.9K
8MIRATI THERAPEUTICS INCCOM4.66%$44M255.2K
9TURNING POINT THERAPEUTICS ICOM4.54%$43M450.4K
10GMEDGLOBUS MED INChistory →CL A3.80%$36M578.4K
11ARVNARVINAS INChistory →COM3.24%$30M460.0K
12VERASTEM INCCOM2.95%$28M11.20M
13GAMIDA CELL LTDSHS2.86%$27M3.32M
14LEGNLEGEND BIOTECH CORPhistory →SPONSORED ADS2.77%$26M896.6K
15CASI PHARMACEUTICALS INCCOM2.70%$25M10.54M
16IOVAIOVANCE BIOTHERAPEUTICS INChistory →COM2.67%$25M790.2K
17ATARA BIOTHERAPEUTICS INCCOM2.56%$24M1.67M
18STXSSTEREOTAXIS INChistory →COM NEW2.51%$24M3.51M
19INFIQINFINITY PHARMACEUTICALS INChistory →COM2.26%$21M6.58M
20NKTXNKARTA INChistory →COM2.00%$19M570.3K
21ADICET BIO INCCOM1.70%$16M1.22M
22CFMSCONFORMIS INChistory →COM1.37%$13M13.00M
23CONSONANCE HFW ACQUISITION CUNIT 99/99/99991.04%$10M1.00M
24SIO GENE THERAPIES INCCOMMON0.89%$8M3.19M
25CTI BIOPHARMA CORPCOM0.78%$7M2.51M
26CELLECTAR BIOSCIENCES INCCOM PAR0.70%$7M4.07M
27IMMUNOGEN INCCOM0.61%$6M703.8K
28SLNSILENCE THERAPEUTICS PLCADS0.54%$5M222.2K
29RESEARCH ALLIANCE CORP IICOM CL A0.33%$3M300.0K
30DEERFIELD HEALTHCARE TECH ACUNIT 07/16/20250.32%$3M229.8K
31MEDICUS SCIENCES ACQUISITIONUNIT 99/99/99990.32%$3M300.0K
32JIYA ACQUISITION CORPCOM CL A0.31%$3M300.0K
33ARYA SCIENCES ACQU CORP IVCL A0.28%$3M250.0K
34BCTG ACQUISITION CORPCOM0.21%$2M180.0K
35HELIX ACQUISITION CORPCOM CL A0.16%$2M150.0K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q3 2022$7M2Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$24M7Aug 15, 202213F-HRchanges · EDGAR ↗
Q1 2022$59M8May 16, 202213F-HRchanges · EDGAR ↗
Q4 2021$153M15Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$183M17Nov 15, 202113F-HRchanges · EDGAR ↗
Q2 2021$831M32Aug 16, 202113F-HRchanges · EDGAR ↗
Q1 2021$938M35May 17, 202113F-HRchanges · EDGAR ↗
Q4 2020$1.1B38Feb 16, 202113F-HRchanges · EDGAR ↗
Q3 2020$821M27Nov 16, 202013F-HRchanges · EDGAR ↗
Q2 2020$1.7B32Aug 14, 202013F-HRchanges · EDGAR ↗
Q1 2020$1.3B31May 15, 202013F-HRchanges · EDGAR ↗
Q4 2019$1.6B35Feb 14, 202013F-HRchanges · EDGAR ↗
Q3 2019$1.0B30Nov 14, 201913F-HRchanges · EDGAR ↗
Q2 2019$1.4B30Aug 14, 201913F-HRchanges · EDGAR ↗
Q1 2019$1.6B26May 15, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.